Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 301–400 of 1,008
Tsakiridis, T. K., Pond, G. R., Wright, J., Ellis, P. M., Ahmed, N., Abdulkarim, B., Roa, W., Robinson, A. G., Swaminath, A., Okawara, G. S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2328 · Cited by 123
Si, H., Kuziora, M., Quinn, K. J., Helman, E., Ye, J., Liu, F., Scheuring, U., Peters, S., Rizvi, N. A., Brohawn, P. Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3771 · Cited by 114
Bonanno, L., Pavan, A., Dieci, M. V., Liso, E. D., Schiavon, M., Comacchio, G. M., Attili, I., Pasello, G., Calabrese, F., Rea, F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.023 · Cited by 119
Sitthideatphaiboon, P., Galan-Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2859 · Cited by 111
Anscher, M. S., Arora, S., Weinstock, C., Amatya, A., Bandaru, P., Tang, C. Z., Girvin, A. T., Fiero, M. H., Tang, S., Lubitz, R., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6439 · Cited by 126
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 126
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 117
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H., Dietlein, F., He, M. X., Margolis, C. A., Elmarakeby, H. A., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 114
Park, K., Vansteenkiste, J., Lee, K. H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P. J., Tan, D. S. W., Yang, J. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.026 · Cited by 122
Self-citationDurvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1897102 · Cited by 114
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
Petrella, F., Rizzo, S., Attili, I., Passaro, A., Zilli, T., Martucci, F., Bonomo, L. D., Grande, F. D., Casiraghi, M., de Marinis, F., et al. (2023) · Current Oncology · doi:10.3390/curroncol30030239 · Cited by 135
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely
Calles, A., Riess, J. W., & Brahmer, J. R. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280795 · Cited by 118
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 124
Adjuvant and Neoadjuvant Immunotherapy in Non–small Cell Lung Cancer
Broderick, S. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.001 · Cited by 113
Immunotherapy in Colorectal Cancer: Current and Future Strategies
Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2020-064 · Cited by 118
Goedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Delaunay, M., Prévôt, G., Collot, S., Guilleminault, L., Didier, A. P., & Mazières, J. (2019) · European Respiratory Review · doi:10.1183/16000617.0012-2019 · Cited by 114
Wang, Y., Zhang, T., Huang, Y., Li, W., Zhao, J., Yang, Y., Li, C., Wang, L., & Bi, N. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.150 · Cited by 121
Self-citationNeurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras, C., Micheli, R. D., Moura, B. G., Hundsberger, T., & Hottinger, A. F. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0810-1 · Cited by 112
Fakhry, C., Blackford, A. L., Neuner, G., Xiao, W., Jiang, B., Agrawal, A., & Gillison, M. L. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0439 · Cited by 114
Akiba, T., Morikawa, T., Odaka, M., Nakada, T., Kamiya, N., Yamashita, M., Yabe, M., Inagaki, T., Asano, H., Mori, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0483 · Cited by 121
Petrelli, F., Ardito, R., Borgonovo, K., Lonati, V., Cabiddu, M., Ghilardi, M., & Barni, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.129 · Cited by 107
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 113
Skribek, M., Rounis, K., Afshar, S., Grundberg, O., Friesland, S., Tsakonas, G., Ekman, S., & Petris, L. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.012 · Cited by 120
Luo, F., Luo, M., Rong, Q., Zhang, H., Chen, Z., Wang, F., Zhao, H.-Y., & Fu, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0733-7 · Cited by 113
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Gutiontov, S. I., Turchan, W. T., Spurr, L. F., Rouhani, S. J., Chervin, C. S., Steinhardt, G., Lager, A. M., Wanjari, P., Malik, R., Connell, P. P., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99524-1 · Cited by 116
Emerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 120
Pan, Y., Zhang, J., Gao, X., Chen, Z., Yan, B., Tan, P., Yang, X., Gao, W., Gong, Y., Tian, Z., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.007 · Cited by 125
Radiotherapy and checkpoint inhibitors: a winning new combination?
Ko, E. C., & Formenti, S. C. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918768240 · Cited by 114
Maity, A. M., Mick, R., Huang, A. C. C., George, S. M., Farwell, M. D., Lukens, J. N., Berman, A. T., Mitchell, T. C., Bauml, J., Schuchter, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0281-9 · Cited by 110
Memmott, R. M., Wolfe, A. R., Carbone, D. P., & Williams, T. M. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.017 · Cited by 118
Hazards of Hazard Ratios — Deviations from Model Assumptions in Immunotherapy
Alexander, B. M., Schoenfeld, J. D., & Trippa, L. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1716612 · Cited by 105
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 114
Contreras, J. A., Lin, A. J., Weiner, A. A., Speirs, C. K., Samson, P. P., Mullen, D. F., Campian, J. L., Bradley, J. D., Roach, M. C., & Robinson, C. G. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.05.017 · Cited by 110
Katsurada, M., Nagano, T., TACHIHARA, M. Y., Kiriu, T., Furukawa, K., KOYAMA, K., Otoshi, T., Sekiya, R., Hazama, D., Tamura, D., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13180 · Cited by 111
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 110
Radiation-Induced Lung Injury—Current Perspectives and Management
Rahi, M. S., Parekh, J., Pednekar, P., Parmar, G., Abraham, S., Nasir, S., Subramaniyam, R., Jeyashanmugaraja, G. P., & Gunasekaran, K. (2021) · Clinics and Practice · doi:10.3390/clinpract11030056 · Cited by 104
Huai, Q., Luo, C., Song, P., Bie, F., Bai, G., Li, Y., Liu, Y., Chen, X., Zhou, B., Sun, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15964 · Cited by 124
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
Welsh, J. W., Heymach, J. V., Guo, C., Menon, H., Klein, K., Cushman, T. R., Verma, V., Hess, K. R., Shroff, G., Tang, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.022 · Cited by 101
Base excision repair regulates PD-L1 expression in cancer cells
Permata, T. B. M., Hagiwara, Y., Sato, H., Yasuhara, T., Oike, T., Gondhowiardjo, S. A., Held, K. D., Nakano, T., & Shibata, A. (2019) · Oncogene · doi:10.1038/s41388-019-0733-6 · Cited by 108
Iyengar, P., Zhang-Velten, E. R., Court, L. E., Westover, K. D., Yan, Y., Lin, M., Xiong, Z., Patel, M., Rivera, D., Chang, J. Y., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3186 · Cited by 101
Cheung, Y.-M. M., Wang, W., McGregor, B. A., & Hamnvik, O. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03128-7 · Cited by 107
Ayoub, N. M., Al-Shami, K. M., & Yaghan, R. J. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s175360 · Cited by 120
Tao, Y., Aupérin, A., Sun, X., Sire, C., Martin, L., Coutte, A., Lafond, C., Miroir, J., Liem, X., Rolland, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.008 · Cited by 101
Skinner, H. D., Hu, C., Tsakiridis, T. K., Santana-Dávila, R., Lü, B., Erasmus, J. J., Doemer, A., Videtic, G. M. M., Coster, J. R., Yang, A. X., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2318 · Cited by 108
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 105
Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S.-H. I., Hellmann, M. D., Kim, S.-W., Ahn, M.-J., Kim, D.-W., Gutierrez, M., Liu, S. V., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.010 · Cited by 97
Self-citationAging, immune senescence, and immunotherapy: a comprehensive review
Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96
Routman, D. M., Garant, A., Lester, S. C., Day, C. N., Harmsen, W. S., Sanheuza, C. T., Yoon, H. H., Neben-Wittich, M. A., Martenson, J. A., Haddock, M. G., et al. (2019) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.09.004 · Cited by 96
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
Ricciuti, B., Leonardi, G. C., Puccetti, P., Fallarino, F., Bianconi, V., Sahebkar, A., Baglivo, S., Chiari, R., & Pirro, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.004 · Cited by 102
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Pavan, A., Attili, I., Pasello, G., Guarneri, V., Conte, P., & Bonanno, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0690-1 · Cited by 104
Mayadev, J., Nunes, A. T., Li, M., Marcovitz, M., Lanasa, M. C., & Monk, B. J. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-001135 · Cited by 98
Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95
Colton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 98
Shen, D., Chen, Q., Wu, J., Li, J., Tao, K., & Jiang, Y. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-599 · Cited by 101
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 120
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 122
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Interfaces between cellular responses to DNA damage and cancer immunotherapy
Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 95
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 95
Hilal, T., González-Vélez, M., & Prasad, V. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2250 · Cited by 93
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Liang, W., Cai, K., Chen, C., Chen, H., Chen, Q., Fu, J., Hu, J., Jiang, T., Jiao, W., Li, S., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2020-63 · Cited by 105
Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies
Raghani, N. R., Chorawala, M. R., Mahadik, M., Patel, R. B., Prajapati, B. G., & Parekh, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-023-02280-7 · Cited by 108
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer
Ostios-García, L., Faig, J., Leonardi, G. C., Adeni, A. E., Subegdjo, S. J., Lydon, C., Rangachari, D., Huberman, M. S., Sehgal, K., Shea, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.031 · Cited by 92
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 91
Immunomodulatory Effects of Radiotherapy
Kumari, S., Mukherjee, S., Sinha, D., Abdisalaam, S., Krishnan, S., & Asaithamby, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218151 · Cited by 106
Luo, R., Firat, E., Gaedicke, S., Guffart, E., Watanabe, T., & Niedermann, G. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1344 · Cited by 91
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
Hanoteau, A., Newton, J. M., Krupar, R., Huang, C. L., Liu, H., Gaspero, A., Gartrell, R. D., Saenger, Y. M., Hart, T. D., Santegoets, S. J. A. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0485-9 · Cited by 102
New pathways in immune stimulation: targeting OX40
Silva, C. A. C., Facchinetti, F., Routy, B., & Derosa, L. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000573 · Cited by 97
Exploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 107
Zhang, X., & Niedermann, G. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.094 · Cited by 98
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
Rashdan, S., Minna, J. D., & Gerber, D. E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30172-3 · Cited by 101
Ruysscher, D. D., Wanders, R., Hendriks, L. E. L., van Baardwijk, A. A. W., Reymen, B. J. T., Houben, R. M. A., Bootsma, G. P., Pitz, C. C. M., van Eijsden, L., & Dingemans, A. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.098 · Cited by 95
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Matos, I. G., Martín-Liberal, J., García-Ruiz, A., Hierro, C., de Olza, M. O., Viaplana, C., Azaro, A., Vieito, M., Braña, I., Mur, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2226 · Cited by 98
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 99
Lim, E. A., Bendell, J. C., Falchook, G. S., Bauer, T. M., Drake, C. G., Choe, J. H., George, D. J., Karlix, J. L., Ulahannan, S. V., Sachsenmeier, K. F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0612 · Cited by 98
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Turgeon, G., Weickhardt, A. J., Azad, A., Solomon, B., & Siva, S. (2018) · The Medical Journal of Australia · doi:10.5694/mja2.12046 · Cited by 97
Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology
Benzekry, S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1951 · Cited by 106
Smit, J., Borm, F. J., Niemeijer, A.-L. N., Huisman, M. C., Hoekstra, O. S., Boellaard, R., Oprea‐Lager, D. E., Vugts, D. J., van Dongen, G. A. M. S., der Veen, B. J. D. W., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262473 · Cited by 103
Shang, S., Liu, J., Verma, V., Wu, M., Welsh, J. W., Yu, J., & Chen, D. (2021) · 癌症:英文版 · doi:10.1002/cac2.12226 · Cited by 99
Rangamuwa, K., Leong, T., Weeden, C. E., Asselin-Labat, M.-L., Bozinovski, S., Christie, M., John, T., Antippa, P. N., Irving, L. B., & Steinfort, D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1075 · Cited by 95
Spyridopoulou, K., Aindelis, G., Pappa, A., & Chlichlia, K. (2021) · Cancers · doi:10.3390/cancers13215335 · Cited by 101
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, D., Lin, J., Yang, X., Long, J., Bai, Y., Yang, X., Mao, Y., Sang, X., Seery, S., & Zhao, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0730-9 · Cited by 90
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 87
Immune checkpoint inhibitors for cancer and venous thromboembolic events
Gong, J., Drobni, Z. D., Alvi, R. M., Murphy, S., Sullivan, R. J., Hartmann, S. E., Gilman, H. K., Lee, H., Zubiri, L., Raghu, V. K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.010 · Cited by 90
Yu, Y., & Lee, N. Y. (2018) · Future Oncology · doi:10.2217/fon-2018-0405 · Cited by 97
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 91
NK cell-based therapeutics for lung cancer
Pockley, A. G., Vaupel, P., & Multhoff, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1688298 · Cited by 86
Alard, E. L., Butnariu, A.-B., Grillo, M., Kirkham, C., Zinovkin, D. A., Newnham, L. J., Macciochi, J., & Pranjol, M. Z. I. (2020) · Cancers · doi:10.3390/cancers12071826 · Cited by 100
Bradley, J. D., Sugawara, S., Lee, K. H., Ostoros, G., Demirkazik, A., Zemanová, M., Sriuranpong, V., Gelatti, A. C. Z., Menezes, J. J. D., Żurawski, B. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00036 · Cited by 105
Self-citationEmerging biomarkers for immune checkpoint inhibition in lung cancer
Cyriac, G., & Gandhi, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.006 · Cited by 89
Cheema, P. K., Rothenstein, J. M., Melosky, B. L., Brade, A. M., & Hirsh, V. (2019) · Current Oncology · doi:10.3747/co.25.4096 · Cited by 88
Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
Choi, C., Yoo, G. S., Cho, W. K., & Park, H. C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i20.2416 · Cited by 89
A Primer on Interstitial Lung Disease and Thoracic Radiation
Goodman, C. D., Nijman, S. F. M., Senan, S., Nossent, E. J., Ryerson, C. J., Dhaliwal, I., Qu, X. M., Laba, J. M., Rodrigues, G., & Palma, D. A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.005 · Cited by 92
Saha, D., Martuza, R. L., & Rabkin, S. D. (2018) · Immunotherapy · doi:10.2217/imt-2018-0009 · Cited by 89
Yu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 92
Césaire, M., Thariat, J., Candéias, S. M., Stefan, D., Saintigny, Y., & Chevalier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123793 · Cited by 94
Boeri, M., Milione, M., Proto, C., Signorelli, D., Russo, G. L., Galeone, C., Verri, C., Mensah, M., Centonze, G., Martinetti, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1981 · Cited by 89
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.